These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 30636671)

  • 1. Novel Approaches for Efficient Delivery of Tyrosine Kinase Inhibitors.
    Moradpour Z; Barghi L
    J Pharm Pharm Sci; 2019; 22(1):37-48. PubMed ID: 30636671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor inhibition strategies in oncology.
    Harari PM
    Endocr Relat Cancer; 2004 Dec; 11(4):689-708. PubMed ID: 15613446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoformulations of small molecule protein tyrosine kinases inhibitors potentiate targeted cancer therapy.
    Yin Y; Yuan X; Gao H; Yang Q
    Int J Pharm; 2020 Jan; 573():118785. PubMed ID: 31678384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
    Dassonville O; Bozec A; Fischel JL; Milano G
    Crit Rev Oncol Hematol; 2007 Apr; 62(1):53-61. PubMed ID: 17324578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progresses in polymeric nanoparticles for delivery of tyrosine kinase inhibitors.
    Foroughi-Nia B; Barar J; Memar MY; Aghanejad A; Davaran S
    Life Sci; 2021 Aug; 278():119642. PubMed ID: 34033837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine kinase inhibitors and their unique therapeutic potentialities to combat cancer.
    Zhao Y; Bilal M; Raza A; Khan MI; Mehmood S; Hayat U; Hassan STS; Iqbal HMN
    Int J Biol Macromol; 2021 Jan; 168():22-37. PubMed ID: 33290765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise.
    Westphal M; Maire CL; Lamszus K
    CNS Drugs; 2017 Sep; 31(9):723-735. PubMed ID: 28791656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status of small-molecule tyrosine kinase inhibitors targeting epidermal growth factor receptor in colorectal cancer.
    Kuo T; Fisher GA
    Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S62-70. PubMed ID: 16336751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.
    Hojjat-Farsangi M
    J Drug Target; 2016; 24(3):192-211. PubMed ID: 26211367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing target therapy against oncogenic tyrosine kinase in myeloid maliganacies.
    Naoe T
    Curr Pharm Biotechnol; 2006 Oct; 7(5):331-7. PubMed ID: 17076649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials.
    Funakoshi T; Latif A; Galsky MD
    Cancer Treat Rev; 2014 Jun; 40(5):636-47. PubMed ID: 24629273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion.
    Bunn PA; Thatcher N
    Oncologist; 2008; 13 Suppl 1():37-46. PubMed ID: 18263773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.
    Yewale C; Baradia D; Vhora I; Patil S; Misra A
    Biomaterials; 2013 Nov; 34(34):8690-707. PubMed ID: 23953842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of tyrosine kinase inhibitors in cancer therapy.
    Arora A; Scholar EM
    J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies.
    Gialeli Ch; Kletsas D; Mavroudis D; Kalofonos HP; Tzanakakis GN; Karamanos NK
    Curr Med Chem; 2009; 16(29):3797-804. PubMed ID: 19747140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and in vitro evaluation of core-shell type lipid-polymer hybrid nanoparticles for the delivery of erlotinib in non-small cell lung cancer.
    Mandal B; Mittal NK; Balabathula P; Thoma LA; Wood GC
    Eur J Pharm Sci; 2016 Jan; 81():162-71. PubMed ID: 26517962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mAb MDR1-modified chitosan nanoparticles overcome acquired EGFR-TKI resistance through two potential therapeutic targets modulation of MDR1 and autophagy.
    Zheng Y; Su C; Zhao L; Shi Y
    J Nanobiotechnology; 2017 Oct; 15(1):66. PubMed ID: 28978341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.